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Abstract
The Blood–brain barrier (BBB), present at the level of the endothelium of cerebral blood vessels, selectively restricts
the blood-to-brain paracellular diffusion of compounds; it is mandatory for cerebral homeostasis and proper
neuronal function. The barrier properties of these specialized endothelial cells notably depend on tight junctions
(TJs) between adjacent cells: TJs are dynamic structures consisting of a number of transmembrane and
membrane-associated cytoplasmic proteins, which are assembled in a multimolecular complex and acting as a
platform for intracellular signaling. Although the structural composition of these complexes has been well
described in the recent years, our knowledge about their functional regulation still remains fragmentary.
Importantly, pericytes, embedded in the vascular basement membrane, and perivascular microglial cells, astrocytes
and neurons contribute to the regulation of endothelial TJs and BBB function, altogether constituting the so-called
neurovascular unit.
The present review summarizes our current understanding of the structure and functional regulation of endothelial
TJs at the BBB. Accumulating evidence points to a correlation between BBB dysfunction, alteration of TJ complexes
and progression of a variety of CNS diseases, such as stroke, multiple sclerosis and brain tumors, as well as
neurodegenerative diseases like Parkinson’s and Alzheimer’s diseases. Understanding how TJ integrity is controlled
may thus help improve drug delivery across the BBB and the design of therapeutic strategies for neurological
disorders.
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Background
The BBB maintains the homeostasis of the central
nervous system (CNS) by (i) strictly limiting the passive
diffusion of polar substances from the blood to the brain,
(ii) mediating the transport of nutrients to the brain par-
enchyma as well as the efflux from the brain of toxic
metabolites and xenobiotics, (iii) regulating the migration
of circulating immune cells [1-3]. Formed by specialized
vascular endothelial cells, the BBB is tightly controlled by
pericytes, embedded in the vascular basement membrane,
perivascular microglial cells, astrocytes and neurons which
altogether constitute the neurovascular unit (NVU), a
concept highlighting the functional cell-cell interactions
supporting BBB function.
BBB endothelial cells display a unique phenotype char-
acterized by the presence of TJs and the expression of
specific polarized transport systems. TJs constitute the
most apical intercellular junctional complex in polarized
epithelium and endothelium, with three key biological
functions: a barrier to paracellular diffusion of blood-
borne polar substances [4], a fence preventing the lateral
diffusion of lipids and integral membrane proteins, thus
maintaining cell polarization [5-7] and an intracellular
signaling platform which will be described below.
Brain endothelial TJ strands, like epithelial TJs, are
composed of integral membrane proteins (occludin,
claudins and junctional adhesion molecules (JAMs))
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involved in intercellular contacts and interactions with
cytoplasmic scaffolding proteins such as zonula occludens
(ZO) proteins, actin cytoskeleton and associated proteins,
such as protein kinases, small GTPases [8] and heterotri-
meric G-proteins [9].
Excellent reviews have recently been published on the
architecture of TJ complexes in epithelial and brain
endothelial cells [10,11]. Here we will briefly recall the
main features of the structural organization of TJs at the
BBB and will focus on transcriptional regulation, post-
translational modifications and subcellular localization
of TJ proteins and their consequences for BBB integrity
with exposure to various environmental stimuli and
during CNS disorders.
Components of TJs in brain endothelial cells
As in polarized epithelial cells where TJs have been
mostly studied, the TJ backbone in brain endothelial
cells consists of transmembrane proteins (occludin,
claudins and JAMs) which recruit a number of
membrane-associated cytoplasmic proteins.
Transmembrane proteins as the BBB TJ backbone
Occludin (60kDa), a tetraspan integral membrane pro-
tein, was the first TJ-specific protein identified [12,13] in
epithelial cells and shown to be functionally important
for barrier function [14]. It is a member of the family
of TJ-associated marvel proteins (TAMP) with tricellu-
lin (marvelD2) [15] and marvelD3 [16,17]. Both the
MARVEL transmembrane domain of occludin, encom-
passing the four transmembrane helices, and its coiled
coil cytosolic C-terminus were recently described to
mediate its lateral (i.e. cis-) oligomerization in epithelial
MDCK cells [18-20]. More precisely, cystein residues in
these domains are directly involved in oligomerization
through disulfide bridge formation. This process being
redox-sensitive, oligomerization of occludin likely con-
tributes to the redox-dependency of the TJ assembly
[20,21]: whereas normoxia conditions support occludin
oligomerization and contribute to TJ assembly, oxidative
stress associated with hypoxia-reoxygenation [22] or in-
flammation [23,24] results in TJ disruption. This novel
concept that occludin plays a key role in the redox regu-
lation of TJs has been very recently reviewed [25].
In addition, the second extracellular domain of occlu-
din is required for its stable assembly in TJs [26]. Indeed,
synthetic peptides corresponding to this domain were
shown to perturb TJ permeability barrier in epithelial
cells [27-29]. The important contribution of occludin to
TJ function is illustrated by the observations that ectopic
expression of chicken occludin induced the formation of
TJ-like structures in Sf9 insect cells [30], while increasing
electrical resistance in MDCK cells [31]. Conversely,
occludin degradation induced by viruses or bacteria (like
HIV-1 Tat protein or Neisseria meningitidis), is associated
with increased permeability in primary or immortalized
human brain microvascular endothelial cells, respectively
[32,33]. However, well-developed TJ strands were reported
in cells lacking occludin (human or guinea pig testis) [34]
and between adjacent occludin-deficient epithelial cells
[34,35]; together with the report that occludin deficient-
mice are viable, exhibiting normal TJs morphology as well
as intestinal epithelium barrier function, these observations
indicate that occludin is dispensable for TJ formation
[36,37].
Claudins constitute a large family of 20-27kDa mem-
brane proteins (with four transmembrane domains)
expressed in TJs in various cell types [4,38-40] (endothe-
lial and epithelial cells). Brain endothelial cells predomin-
antly express claudin-3 and claudin-5 [41,42], claudin-12
likely being also expressed [43,44]. A large corpus of data
clearly establishes the key contribution of claudin-3 and
claudin-5 to TJ formation and integrity at the BBB.
Indeed, exogenous expression of claudin-5 strengthens
barrier properties in cultured rat brain endothelial cells
[44], whereas depletion of claudin-5 induces the disrup-
tion of the BBB in genetically-altered mice [43] and in
cultured human brain endothelial cells [9]. Claudins sup-
port TJ integrity via their capacity of cis- and trans-
homodimerization as well as heterodimerization, notably
through their second extracellular loop, as recently
reported for claudin-5 [45-47]. Claudin-5 can interact
with claudin-3 [48,49] and the selective loss of the latter
during autoimmune encephalomyelitis or human glio-
blastoma is associated with BBB breakdown [41].
Beside occludin and claudins, JAMs, although not
essential to TJ formation in epithelial and endothelial
cells, may be involved in the facilitation of assembly of
TJ components and in the establishment of cell polarity
by recruiting the polarity complex (Par-3/Par-6/aPKC:
see below) to TJs [50,51].
Membrane-associated cytoplasmic proteins in BBB TJs
A number of cytoplasmic proteins have been described
to associate with TJ transmembrane proteins and to
contribute somehow to TJ integrity in epithelial and
brain endothelial cells. Among them, the PDZ domain-
containing, membrane-associated guanylate kinase
(MAGUK) family members have been largely documented:
zonula occludens-1 (ZO-1, 225kDa) [52], ZO-2 (160kDa)
[53], and ZO-3 (130kDa) [54]. ZO-1 forms heterodimers
with ZO-2 and ZO-3 [54-56]. ZO proteins interact with the
C-terminal domain of claudins via their first PDZ domain
(PDZ1) [57], to JAMs by the third PDZ domain (PDZ3)
[58] and to occludin via their GUK domains [55,56,59]. It
is well established that ZO proteins are essential to the
assembly of claudins [60], occludin [35] and JAM-A [61]
at TJs, then anchoring this multimolecular complex to
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the actin cytoskeleton [62]. Par-3 (also known as ASIP)
[63] binds to JAM proteins [64-66] and recruits to TJs
atypical protein kinase C [67] and Par-6 [68], the three
proteins then forming a Planar Cell Polarity (PCP)
complex in polarized epithelial cells [69]. Only very recently
was their expression confirmed also in brain endothelial
cells [70].
Among additional TJ-associated proteins, heterotrimeric
G-proteins (Gαi) were first described, in association with
ZO-1, to contribute to TJ biogenesis and maintenance in
epithelial and brain endothelial cells [71-73]. Gαi2 proteins
were reported to be involved in T-lymphocyte extravasa-
tion, including in brain [74,75]. More recently, we reported
that Gαi2 interacts with claudin-5 and that its depletion
increases brain endothelial cell permeability in vitro and
delays TJ reassembly after hyperosmotic shock (induced by
a high concentration mannitol treatment) [9]. On the basis
of these observations, we proposed that claudin-5 and
Gαi2, whether they interact directly or indirectly, might
control TJ integrity as components of a multiprotein com-
plex, including caveolin, ZO-1 linked to the actin cytoskel-
eton and possibly also, occludin and MUPP-1.
Physiological regulation of TJ assembly by the
NVU
The NVU: regulation of TJ assembly by perivascular cells
Developmental role of astrocyte and pericyte secreted
proteins
Development and maintenance of the BBB requires
functional interactions between endothelial cells and
perivascular cells of the NVU: whereas astrocytes have
been well documented to regulate BBB formation and
integrity [76,77], only recently was the role of pericytes
unraveled (for reviews: [78-80]).
Indeed, early studies using co-culture of cerebral endo-
thelial cells and astrocytes (or culture in the presence of
astrocyte-conditioned medium) [81-87] highlighted the
role of astrocyte-derived soluble factors in maintaining
the specialized phenotype of brain endothelial cells
(Figure 1). In addition, more recent reports established
that pericytes also actively contribute to BBB formation
during development by the release of several growth
factors and morphogens [88-91].
Astrocyte- and pericyte-derived Wnt and hedgehog
morphogens were reported to control BBB formation
during development and TJ integrity. Indeed, the Wnt/
β-catenin pathway has been recently discovered as a
major BBB-regulating pathway. Wnt ligation to its mem-
brane receptors, Frizzled4 (Fz4) and LRP5/6 expressed
by brain endothelial cells, inhibits the β-catenin repres-
sor complex, allowing β-catenin cytoplasmic accumula-
tion, nuclear translocation and transcription of various
genes, including claudin-3 in cultured murine brain
endothelial cells [96,99] (Figure 1). Moreover, in vivo
inactivation of Wnt factors (Wnt7a and Wnt7b) [100],
Fz4 receptor [101] or injection of a soluble inhibitor of
the Wnt/ Frizzled receptor interaction [102] lead to
major vascular defects in the CNS (interestingly, not in
non-neuronal tissues) and to BBB breakdown, clearly
demonstrating a specific role for the Wnt/β-catenin
pathway in BBB differentiation during development and
for BBB maintenance in adulthood. These exciting
observations (for review, see: [103]) open new research
avenues for controlling BBB permeability in pathological
situations as well as improving drug delivery to the CNS.
Sonic hedgehog (Shh), another well-known morphogen
protein, acting through its membrane receptors Patched-
1 (Ptch1)/Smoothened (Smo), was also recently shown
to control BBB differentiation and to maintain the im-
mune privilege of the CNS by inhibiting the endothelial
production of chemokines and expression of adhesion
proteins supporting extravasation of leukocytes to the
brain [95].
In conclusion, these recent findings further document,
at the molecular and cellular levels, the functional inter-
actions between brain endothelial cells, pericytes and
astrocytes and emphasise the key importance of the
NVU in controlling BBB permeability and integrity. The
major cellular cross-talks at the NVU are illustrated in
Figure 1.
Role of basement membrane-associated proteins
The vascular basement membrane (or basal lamina) is a
complex structure, composed of four glycoprotein fam-
ilies: laminins, collagen type IV, nidogens and heparan
sulfate proteoglycans. Recent studies have unraveled the
contribution of the endothelial laminin isoform α5 to
the barrier property of the BBB by selectively inhibiting
lymphocyte infiltration; the basement membrane thus
contributes to maintain the well-known “immune privilege”
of the CNS [104].
The heparan sulfate proteoglycan agrin is found in the
basal lamina of brain microvessels [105]. A strict positive
correlation has been reported between agrin deposition
and expression of occludin [106], whereas, conversely,
absence of agrin in glioblastoma vessels was shown to
correlate with the lack of TJ proteins (occludin, claudin-5):
these observations strongly suggest that agrin may regu-
late TJ formation in brain endothelium. Recently, agrin
was described to be involved in the development of the
BBB by contributing to astrocyte polarity [92]. More-
over, β1-integrin-mediated attachment of brain endo-
thelial cells to the basement membrane has also been
reported to be critical for stabilizing claudin-5 localization
at TJs and maintaining BBB integrity in vitro and in vivo
[93]. Genetic deletion of β1-integrin decreases the ex-
pression of the polarity protein Par-3, leading to the
loss of endothelial cell polarity: these recent data
Luissint et al. Fluids and Barriers of the CNS 2012, 9:23 Page 3 of 12
http://www.fluidsbarrierscns.com/content/9/1/23
suggest that β1-integrin-mediated brain endothelial cell
adhesion to the basement membrane may lead to the
development of cell polarity, TJ formation and BBB
integrity [94].
VE-cadherin and β-catenin as modulators of TJs
In addition to TJs, junctional complexes between endo-
thelial cells include adherens junctions (AJs), constituted
by transmembrane proteins VE-cadherin linked to the
actin cytoskeleton through catenins (eg: p120-catenin,
α- and β-catenin) [107-109]. Interestingly, AJ and TJ
complexes functionally interact in brain endothelial
cells: indeed, VE-cadherin engagement induces claudin-5
transcription through inhibition of FoxO1 activity (a
transcription repressor of claudin-5 gene) and β-catenin
sequestration (a stabilizer of FoxO1 activity) in AJ
complexes [97], in line with the above-mentioned cap-
acity of β-catenin, downstream of Wnt receptor activa-
tion, to control claudin gene expression [96]. These
findings clearly place VE-cadherin upstream of claudin-5
in the establishment, maturation and maintenance of
endothelial cell-cell junctions.
Contribution of shear stress to TJ modulation and
BBB integrity
It is established that one important mechanical stimu-
lus contributing to BBB formation and maintenance is
shear stress [110], a tangential force generated by flow
across the apical surface of vascular endothelium
[111,112]. In line with the accepted concept that cere-
bral microcirculation is highly heterogeneous, mean
shear stress levels in brain microvessels has been
Figure 1 Schematic representation of TJ modulation by the NVU. (a) The basal lamina protein agrin increases claudin-5 (Cld5) and occludin
expression [92]; (b) Aquaporin-4 density, regulated by agrin, stabilizes TJ complexes through ZO-1 expression [93]; (c) β1-integrin engagement
stabilizes Cld5 localization at the TJ [94]; (d) astrocyte/pericyte-secreted TGF-β induces Cld5 transcription through activation of Smad transcription
factor [91]; (e) Shh enhances expression of TJ proteins via its membrane receptor Ptch1/Smo and the transcription factor Gli-1 [95]; (f) Endothelial
PDGF-β recruits pericytes which stabilize BBB phenotype [90]; (g) Wnt 7a/7b proteins, via their membrane receptors Frizzled-4 associated to
LRP5/6, induce Cld3 transcription through stabilization of β-catenin [96]; (h,i,j) Angiopoietin-1 (Ang1), via its membrane receptor Tie2, enhances
VE-Cadherin clustering and Cld5 transcription through inhibition of FoxO1 activity by PI3K and β-catenin sequestration [83,97] ; (k) VE-Cadherin
engagement recruits CCM1 and the polarity complex (PCP) leading to TJ stabilization [98].
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estimated in a range as wide as 0.01 to 10 dynes/cm2
in capillaries and 10–100 dynes/cm2 in arterioles [113-115].
Several dynamic in vitro models were developed in order
to mimic a physiological situation (using laminar, steady
flow) or a pathological condition (such as atheroscler-
osis), using an irregular flow. Interestingly, culturing
human umbilical vein endothelial cells (HUVECs) in a
laminar flow chamber in the presence of meningococci
(N. meningitidis) was instrumental for unraveling some
key molecular mechanisms of CNS invasion by these
meningitis-causing human pathogens [111]. Regarding
BBB differentiation, culture of brain endothelial cells
under flow has been reported to induce the expression of
the TJ proteins occludin and ZO-1, to promote actin
cytoskeleton reorganization and to reduce endothelial
permeability [113,115-117]. In addition, very recent find-
ings suggest that physiological shear stress (6 dynes/cm2)
may increase the expression of a variety of BBB-
associated genes in human brain microvascular endo-
thelial cells, such as genes encoding for TJ proteins
(ZO1, claudin-3, claudin-5), several influx transporters
(Glut-1) and multidrug resistance efflux transporters
(ABCB1/P-gp, ABCC5/MRP5) [116]. Nevertheless, fur-
ther investigation is still required to get a better under-
standing of the contribution of shear stress to the
maintenance of BBB integrity.
Dysregulation of the BBB via phosphorylation and
relocalization of TJ proteins
Studies on CNS diseases associated with BBB dysfunctions
(e.g. stroke, multiple sclerosis, cerebral infection, brain
tumors, Parkinson’s and Alzheimer’s diseases) have pointed
to various molecular mechanisms involved in disruption of
TJ integrity, notably including Serine/Threonine (Ser/Thr)-
and Tyrosine (Tyr)-phosphorylation, down-regulation,
degradation or translocation of TJ proteins; a non ex-
haustive list of related reports are presented in Table 1.
More than other TJ proteins (such as claudins or JAMs),
occludin has been the focus of numerous studies investi-
gating post-translational modifications and their conse-
quences on TJ integrity (see for review: [118,119]).
Table 1 Dysregulation of the BBB via phosphorylation or down-regulation of TJ proteins
TJ proteins modifications Targeted TJ proteins Signaling pathway Stimulus / Diseases References
Serine/Threonine
Phosphorylation
Cld5 (Thr207) PKA cAMP [120]
Cld5, Occludin and ZO-1 nPKC-θ / aPKC-ζ Hypoxia [121]
N.D. cPKC-α, cPKC-βII , aPKC-λ/ζ HIV-1 gp120 [122]
Cld5 (T207) Occludin (T382/S507) RhoA/Rho kinase HIV-1 encephalitis [123]
Cld5, Occludin, ZO-1 RhoA / PKC-α CCL2 chemokine [124]
Cld5 and Occludin MLCK Alcohol / Reactive oxygen species [125,126]
N.D. Hypoxia / Reactive oxygen species [127]
Tyrosine Phosphorylation Occludin c-Src Cerebral ischemia [128]
Occludin N.D. Glutamate [129]
Cld5 N.D. TGF-β [130]
ZO-1 ND Tyrosine phosphatase inhibition [131]
Down-regulation
or degradation
Cld5 and Occludin
Internalization
Caveolae-dependent
endocytosis
CCL2 chemokine [132]
Occludin JNK, p38MAPK Amyloid-β peptide [133]
Cld5 ERK1/2 HIV-1 Tat protein [134]
Occludin and ZO-1 distribution PLC-γ, PI3K/Akt Hypoxia [135]
N.D. [136]
Cld5 N.D. [137]
Cld5 and Occludin VEGFR VEGF [138]
Cld3 N.D. Multiple Sclerosis Glioblastoma
multiforme
[41]
Cld5, Occludin, ZO-1 nPKC-δ Cerebral ischemia [139]
Occludin and ZO-1 MLCK HTLV-1 [140]
Cld5 and Occludin RhoA/RhoK Reactive oxygen species [141]
N.D : Not Described.
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Ser/Thr-phosphorylation of TJ proteins and regulation
of barrier permeability
Ser/Thr-phosphorylation forms of occludin are found
concentrated at TJs whereas dephosphorylated occludin
is rather detected on basolateral membranes and asso-
ciated with disrupted TJs in epithelial cells [142,143]
as well as in brain endothelial cells in experimental auto-
immune encephalomyelitis, a murine model of multiple
sclerosis characterized by brain inflammation [144].
Regarding claudin-5, phosphorylation of its C-terminal
domain on Thr207 residue in response to PKA or Rho
kinase activation [120,123,145] generally affected TJ integ-
rity in brain endothelial cells and increased permeability.
Differential regulation of TJs by Protein Kinases C (PKCs)
PKC-dependent pathways have been involved in endothe-
lial barrier disruption, as reported following treatment by
pertussis toxin, an inhibitor of Gαi heterotrimeric G
proteins [146], or in response to the pro-inflammatory
cytokine interleukin-6 (IL-6) which plays a critical role
during hypoxia [147]. However, early reports had clearly
established that PKC activity was crucial for BBB integrity
in epithelial cells, inasmuch as PKC inhibitors completely
blocked the formation of TJs [148,149]; in addition, PKC-
mediated phosphorylation of occludin (on residue Ser338)
was involved in occludin targeting to TJs and TJ
stabilization in epithelial MDCK cells [148].
At least part of the interpretation of these apparently
conflicting data may be found in the heterogeneity of
the PKC family. The Ser/Thr-kinases PKCs are indeed
classified into conventional (cPKC: α, βI, βII and γ),
novel (nPKC: δ, ε, θ, η, μ) and atypical (aPKC: λ,ζ) PKC
isozymes [150] according to their modes of regulation.
Accumulating evidence has pointed to a differential
capacity of PKC isozymes to regulate BBB permeability.
Indeed, activation of nPKC-θ and aPKC-ζ signaling by
hypoxia-mediated TJ proteins results in relocalization
(such as claudin-5, occludin, ZO-1) and increased BBB
permeability in rat brain microvascular endothelial cells
(in vitro and in vivo) [121,151]. In human brain micro-
vascular endothelial cells, cPKCα, cPKC βII and aPKCλ/ζ
isoforms were activated by HIV-1 gp120 envelope pro-
tein, leading to BBB disruption, intracellular calcium
increase and monocyte migration across cell monolayer
[122]. Interestingly, when cPKC-α was found to con-
tribute to TJ disassembly, nPKC-ε activation mediated
TJ formation in epithelial MDCK cells [152]. In line
with this observation, over-expression of cPKC-α in rat
epididymal microvascular endothelial cells was reported
to enhance thrombin-induced permeability, whereas
nPKC-δ expression promoted barrier function [153].
By contrast, IL-25, expressed by mouse brain capillary
endothelial cells, was shown to prevent inflammation-
induced BBB disruption and down-regulation of TJ
proteins (occludin, claudin-5, JAMs) through activation
of the nPKC-ε pathway [154]. Altogether, these obser-
vations strongly suggest that nPKC-selective activation
generally contributes to maintaining barrier integrity,
whereas cPKC activation has the opposite effect, both
in polarized epithelium and endothelium (Table 1).
Regarding aPKC isoforms (λ and ζ), they have been
shown to contribute to the establishment of epithelial
cell polarity, via participation in the PCP complex to-
gether with Par-3 and Par-6 [63,68,155]. As mentioned
above, the PCP complex is recruited to endothelial TJs by
Par-3 binding to JAM proteins [64-66]. Over-expression
of a dominant negative mutant of aPKC causes mislocali-
zation of Par-3 and affects the biogenesis of the TJs in
epithelial cells [67], suggesting that Par-3 is a substrate of
aPKC and that its localization in epithelial cells is
dependent upon its phosphorylation. In the same line,
the VE-cadherin/CCM1 (a protein encoded by the
CCM1 gene which is mutated in a large proportion
of patients affected by cerebral cavernous malforma-
tion) complex controls aPKC-ζ activation and Par-3
localization during early steps of brain endothelial cell
polarization [98]. The participation of this PCP complex
to TJ integrity was further illustrated by the recent obser-
vation that meningococcal adhesion to human cerebral
endothelial cells recruited Par-3, Par-6 and aPKC-ζ under
bacterial colonies and induced disruption of cell-cell
junctions [156]. Surprisingly, a distinct Par-3/Par-6 com-
plex, directly associated with VE-cadherin and lacking
aPKC, has also been identified in endothelial cells [157].
Finally, although additional polarity complexes are
known in epithelial cells (the apical Crumbs complex and
the basolateral Scribble complex) where they also con-
tribute to TJ formation and regulation, no similar obser-
vations have been reported, to our knowledge, in brain
endothelial cells.
BBB disruption mediated by Rho/ Rho kinase and MLCK
activation
The RhoA GTPase signaling pathway, activated by several
membrane receptors, has been extensively documented in
various cell types to induce actin cytoskeleton rearrange-
ments involved in cell migration and proliferation. In
brain endothelial cells, RhoA activation increased perme-
ability, in response to inflammatory stimuli, through one
of its major effectors Rho kinase (ROCK) [158,159].
Among these inflammatory stimuli, chemokines like
MCP-1/CCL2, acting via their seven transmembrane-
domain receptors, are known to activate the RhoA/ROCK
pathway in mouse brain endothelial cells, to induce occlu-
din, claudin-5 and ZO-1 Ser/Thr-phosphorylation, fol-
lowed by their delocalization from TJs, ultimately leading
to increased barrier permeability [124,160]. Similarly,
enhanced monocyte migration across human brain
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endothelial cells was observed in an HIV-1 encephalitis
model [123,161]. Also, adhesion molecules like ICAM-1
and VCAM-1 were shown, in response to lymphocyte/
monocyte adhesion, to transduce signals in rat brain
endothelial cell lines including activation of the RhoA/
ROCK pathway [162,163]: activation of this pathway ul-
timately leads to enhanced lymphocyte migration, sug-
gesting that this process may be involved in the massive
infiltration of immune cells into the CNS observed in
multiple sclerosis. It must be mentioned, however, that
lymphocyte migration across the BBB may also happen
via a transcellular pathway, leaving intact endothelial TJs
[164].
Rearrangements of the actin cytoskeleton have long
been recognized to be regulated, not only by the RhoA/
ROCK pathway, but also, often in a coordinated manner,
by the myosin light chain kinase (MLCK): MLCK dir-
ectly phosphorylates the myosin light chain, leading to
actomyosin contraction and endothelial barrier disruption
[165-167]. In the same line, inhibition of MLCK in bovine
brain endothelial cells was more recently reported to
prevent hypoxia-induced BBB disruption [127], whereas
alcohol increased human brain endothelial cell perme-
ability via activation of MLCK and phosphorylation of
occludin and claudin-5 [125,126]. Recently, pro-
inflammatory cytokines (IL1β and TNFα), secreted by
lymphocytes chronically infected by the HTLV-1 retro-
virus, were reported to induce barrier disruption in the
human brain endothelial cell line hCMEC/D3, associated
with loss of occludin and ZO-1 through activation of the
MLCK pathway [140].
In conclusion, as summarized in Table 1, inflammation-
or infection-induced actin cytoskeleton rearrangements in
brain endothelial cells, mediated by the RhoA/ROCK
and/or MLCK pathways, are associated with the phos-
phorylation, followed by delocalization or degradation of
TJ proteins, and BBB disruption.
BBB dysregulation by Tyr-phosphorylation of TJ proteins
Early studies with cultured bovine brain endothelial cells
and MDCK cells had pointed to Tyr-phosphorylation as a
mechanism for increasing TJ permeability [131]. Accumu-
lating evidence demonstrated that Tyr-phosphorylation of
TJ proteins, as well as AJ proteins, was directly involved in
BBB disruption, as observed in various pathological situa-
tions, although the identity of the Tyr-kinases involved
often remained unknown. Unlike occludin Ser/Thr phos-
phorylation associated with barrier formation, as men-
tioned above, occludin Tyr-phosphorylation was reported
to be associated with increased permeability of cultured
rat brain endothelial cells exposed to glutamate, as a way
to mimic cerebral ischemia [129] (Table 1). Like other
pro-inflammatory cytokines, transforming growth factor
(TGF)-β1 is known to increase BBB permeability: as
recently reported in bovine retinal and human brain
endothelial cells, this effect was mediated by Tyr-
phosphorylation of both claudin-5 and VE-cadherin
[130]. Vascular endothelial growth factor (VEGF), a
major angiogenic factor, which is drastically enhanced in
response to hypoxia, promotes Tyr-phosphorylation of
TJ proteins (ZO-1, occludin) in mouse brain and retinal
endothelial cells [168,169] either directly via its mem-
brane receptor tyrosine kinase VEGFR2 or via the activa-
tion of the cytosolic tyrosine kinase c-src [128,170].
VEGF-mediated Tyr-phosphorylation of TJ proteins in
brain endothelial cells was often followed by their
down-regulation and/or re-localization, leading to TJ
destabilization and permeability increase [136-138,171].
Alterations of expression and localization of TJ proteins
Caveolae are specialized plasma membrane microdo-
mains, abundantly found in endothelial cells where they
mediate various biological events such as transcytosis, vas-
cular permeability and angiogenesis [172,173]. They are
enriched in the small membrane protein caveolin-1 which
has been shown to recruit TJ proteins [9,174]. Caveolae-
mediated endocytosis induced by actin depolymerization
was reported to evoke occludin internalization in MDCK
cells [175]. Interestingly, exposure of cultured rat brain
endothelial cells to the HIV-1 Tat protein was reported to
increase TJ permeability, through alterations in expression
and distribution of TJs proteins: occludin, claudin-5, ZO1,
ZO2 [134,176]. In the same line, the increase in TJ perme-
ability observed in mouse brain endothelial cell response
to the inflammatory cytokine CCL2 was recently shown to
be associated with claudin-5 and occludin internalization
in a caveolae-dependent manner [132]. Altogether these
results strongly support the conclusion that alterations in
expression and localization of TJ proteins, associated or
not with their phosphorylation in response to various
pathological stimuli, directly contribute to TJ disruption
and BBB permeability increase (Table 1); in addition, they
suggest a role of caveolin-1/caveolae in such TJ remodeling.
Conclusion
The brain endothelial TJ complex, which constitutes a
key feature of the BBB, is now understood as a scaf-
folding and signaling platform in close interaction
with the actin cytoskeleton and the AJ complex. It
also appears as a dynamic complex, submitted to
post-translational modifications in response to physio-
logical and pathological stimuli. Indeed, perivascular
cells of the NVU, notably astrocytes and pericytes, se-
crete multiple growth factors and morphogens that
contribute to TJ formation and integrity. Conversely,
various pathological situations associated with the
presence of inflammatory cytokines, reactive oxygen
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species or pathogens, lead to TJ disruption following
phosphorylation and/or internalization of TJ proteins.
Although our understanding of TJ architecture and
function has significantly increased over the last ten
years, a number of issues will have to be addressed in
the next future, in particular taking advantage of new
and/or global analysis technologies. For example, super-
resolution light microscopy (time-lapse stimulated emis-
sion depletion (STED) imaging) recently appeared as a
very powerful approach to unravel synapse assembly and
plasticity [177]; in the same line, super-resolution mi-
croscopy of TJs (with a resolution down to 50–80 nm)
of cerebral microvessels in brain slices should provide a
more accurate understanding of TJ organization and
dynamics. Also, thanks to the availability of validated
BBB in vitro models, identification by mass spectrometry
(MS/MS analysis) of the secreted proteins (so-called
‘secretome’) from brain endothelial co-cultures with
astrocytes or pericytes may unravel new paracrine signal-
ing pathways in the NVU which contribute to the
stabilization of TJs at the BBB; in addition, similar ana-
lyses in the presence of inflammatory agents or patho-
gens [178] may highlight unsuspected mechanisms of TJ
disruption. This approach will complement quantitative
targeted absolute proteomics (also known as selected
reaction monitoring (SRM)), an emerging approach to
quantify membrane proteins [179]. This technology
will also greatly benefit the field, allowing absolute
quantification of TJ proteins in physiological and vari-
ous pharmacological situations, as recently proposed
[180]. The treatment of neurological diseases is cur-
rently hampered by difficulties encountered in deliver-
ing therapeutic compounds to the brain, across the
BBB. Because previous drug delivery strategies based
on transcellular transport machinery have shown lim-
ited efficacy so far, it is tempting to propose that tran-
sient modulation of TJs at the BBB, using in vitro
models of the BBB and in vivo models of human path-
ologies, may constitute an alternative approach for
drug delivery to the brain. Clearly, this field will bene-
fit greatly from an in-depth understanding of TJ archi-
tecture and functional regulatory mechanisms.
Abbreviations
AJ: Adherens junction; BBB: Blood brain barrier; CNS: Central nervous system;
ECL: Extracellular loop; Fz: Frizzled; HUVEC: Human umbilical vein endothelial
cell; IL: Interleukin; JAM: Junctional adhesion molecule; MAGUK: Membrane
associated guanylate kinase; MLCK: Myosin light chain kinase;
NVU: Neurovascular unit; PCP: Planar cell polarity; PKC: Protein kinase C;
Ptch1: Patched-1; ROCK: Rho kinase; Shh: Sonic hedgehog;
Smo: Smoothened; TAMP: Tight junction-associated marvel proteins;
TGF: Transforming growth factor; TJ: Tight junction; VEGF: Vascular
endothelial growth factor; ZO: Zonula occludens.
Competing interests
The authors declare no conflict of interest.
Authors’ contributions
ACL and CA: were responsible for the collection of data and references, and
for the drafting of the document. FG and KG were involved in the collection
of data and drafting of the document. POC was responsible for the drafting
and editing of the document, and for the discussion of the data. All authors
read and approved the final manuscript.
Author details
1INSERM U1016, Institut Cochin, Paris, France. 2CNRS, UMR 8104, Paris, France.
3Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Received: 3 July 2012 Accepted: 21 October 2012
Published: 9 November 2012
References
1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ: Structure and
function of the blood–brain barrier. Neurobiol Dis 2010, 37:13–25.
2. Begley DJ, Brightman MW: Structural and functional aspects of the
blood–brain barrier. Prog Drug Res 2003, 61:39–78.
3. Wolburg H, Noell S, Mack A, Wolburg-Buchholz K, Fallier-Becker P: Brain
endothelial cells and the glio-vascular complex. Cell Tissue Res 2009,
335:75–96.
4. Tsukita S, Furuse M, Itoh M: Multifunctional strands in tight junctions. Nat
Rev Mol Cell Biol 2001, 2:285–293.
5. Cereijido M, Valdes J, Shoshani L, Contreras RG: Role of tight junctions in
establishing and maintaining cell polarity. Annu Rev Physiol 1998,
60:161–177.
6. Gumbiner BM: Breaking through the tight junction barrier. J Cell Biol 1993,
123:1631–1633.
7. Schneeberger EE, Lynch RD: Structure, function, and regulation of cellular
tight junctions. Am J Physiol 1992, 262:L647–661.
8. Vorbrodt AW, Dobrogowska DH: Molecular anatomy of intercellular
junctions in brain endothelial and epithelial barriers: electron
microscopist’s view. Brain Res Brain Res Rev 2003, 42:221–242.
9. Luissint AC, Federici C, Guillonneau F, Chretien F, Camoin L, Glacial F,
Ganeshamoorthy K, Couraud PO: Guanine nucleotide-binding protein
Galphai2: a new partner of claudin-5 that regulates tight junction
integrity in human brain endothelial cells. J Cereb Blood Flow Metab 2012,
32:860–873.
10. Aijaz S, Balda MS, Matter K: Tight junctions: molecular architecture and
function. Int Rev Cytol 2006, 248:261–298.
11. Redzic Z: Molecular biology of the blood–brain and the blood-
cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS
2011, 8:3.
12. Ando-Akatsuka Y, Saitou M, Hirase T, Kishi M, Sakakibara A, Itoh M,
Yonemura S, Furuse M, Tsukita S: Interspecies diversity of the occludin
sequence: cDNA cloning of human, mouse, dog, and rat-kangaroo
homologues. J Cell Biol 1996, 133:43–47.
13. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S: Occludin: a
novel integral membrane protein localizing at tight junctions. J Cell Biol
1993, 123:1777–1788.
14. Balda MS, Whitney JA, Flores C, Gonzalez S, Cereijido M, Matter K:
Functional dissociation of paracellular permeability and transepithelial
electrical resistance and disruption of the apical-basolateral
intramembrane diffusion barrier by expression of a mutant tight
junction membrane protein. J Cell Biol 1996, 134:1031–1049.
15. Ikenouchi J, Furuse M, Furuse K, Sasaki H, Tsukita S: Tricellulin constitutes a
novel barrier at tricellular contacts of epithelial cells. J Cell Biol 2005,
171:939–945.
16. Raleigh DR, Marchiando AM, Zhang Y, Shen L, Sasaki H, Wang Y, Long M,
Turner JR: Tight junction-associated MARVEL proteins marveld3,
tricellulin, and occludin have distinct but overlapping functions. Mol Biol
Cell 2010, 21:1200–1213.
17. Steed E, Rodrigues NT, Balda MS, Matter K: Identification of MarvelD3 as a
tight junction-associated transmembrane protein of the occludin family.
BMC Cell Biol 2009, 10:95.
18. Yaffe Y, Shepshelovitch J, Nevo-Yassaf I, Yeheskel A, Shmerling H, Kwiatek
JM, Gaus K, Pasmanik-Chor M, Hirschberg K: The MARVEL transmembrane
motif of occludin mediates oligomerization and targeting to the
basolateral surface in epithelia. J Cell Sci 2012, 125:3545–3556.
Luissint et al. Fluids and Barriers of the CNS 2012, 9:23 Page 8 of 12
http://www.fluidsbarrierscns.com/content/9/1/23
19. Blasig IE, Winkler L, Lassowski B, Mueller SL, Zuleger N, Krause E, Krause G,
Gast K, Kolbe M, Piontek J: On the self-association potential of
transmembrane tight junction proteins. Cell Mol Life Sci 2006, 63:505–514.
20. Walter JK, Castro V, Voss M, Gast K, Rueckert C, Piontek J, Blasig IE: Redox-
sensitivity of the dimerization of occludin. Cell Mol Life Sci 2009,
66:3655–3662.
21. Walter JK, Rueckert C, Voss M, Mueller SL, Piontek J, Gast K, Blasig IE: The
oligomerization of the coiled coil-domain of occludin is redox sensitive.
Ann N Y Acad Sci 2009, 1165:19–27.
22. Lochhead JJ, McCaffrey G, Quigley CE, Finch J, DeMarco KM, Nametz N,
Davis TP: Oxidative stress increases blood–brain barrier permeability and
induces alterations in occludin during hypoxia-reoxygenation. J Cereb
Blood Flow Metab 2010, 30:1625–1636.
23. Lochhead JJ, McCaffrey G, Sanchez-Covarrubias L, Finch JD, Demarco KM,
Quigley CE, Davis TP, Ronaldson PT: Tempol modulates changes in
xenobiotic permeability and occludin oligomeric assemblies at the
blood–brain barrier during inflammatory pain. Am J Physiol Heart Circ
Physiol 2012, 302:H582–593.
24. McCaffrey G, Seelbach MJ, Staatz WD, Nametz N, Quigley C, Campos CR,
Brooks TA, Davis TP: Occludin oligomeric assembly at tight junctions of
the blood–brain barrier is disrupted by peripheral inflammatory
hyperalgesia. J Neurochem 2008, 106:2395–2409.
25. Blasig IE, Bellmann C, Cording J, Del Vecchio G, Zwanziger D, Huber O,
Haseloff RF: Occludin protein family: oxidative stress and reducing
conditions. Antioxid Redox Signal 2011, 15:1195–1219.
26. Medina R, Rahner C, Mitic LL, Anderson JM, Van Itallie CM: Occludin
localization at the tight junction requires the second extracellular loop.
J Membr Biol 2000, 178:235–247.
27. Wong V, Gumbiner BM: A synthetic peptide corresponding to the
extracellular domain of occludin perturbs the tight junction permeability
barrier. J Cell Biol 1997, 136:399–409.
28. Tavelin S, Hashimoto K, Malkinson J, Lazorova L, Toth I, Artursson P: A new
principle for tight junction modulation based on occludin peptides.
Mol Pharmacol 2003, 64:1530–1540.
29. Everett RS, Vanhook MK, Barozzi N, Toth I, Johnson LG: Specific modulation
of airway epithelial tight junctions by apical application of an occludin
peptide. Mol Pharmacol 2006, 69:492–500.
30. Furuse M, Fujimoto K, Sato N, Hirase T, Tsukita S: Overexpression of
occludin, a tight junction-associated integral membrane protein, induces
the formation of intracellular multilamellar bodies bearing tight
junction-like structures. J Cell Sci 1996, 109(Pt 2):429–435.
31. McCarthy KM, Skare IB, Stankewich MC, Furuse M, Tsukita S, Rogers RA,
Lynch RD, Schneeberger EE: Occludin is a functional component of the
tight junction. J Cell Sci 1996, 109(Pt 9):2287–2298.
32. Schubert-Unkmeir A, Konrad C, Slanina H, Czapek F, Hebling S, Frosch M:
Neisseria meningitidis induces brain microvascular endothelial cell
detachment from the matrix and cleavage of occludin: a role for MMP-8.
PLoS Pathog 2010, 6:e1000874.
33. Xu R, Feng X, Xie X, Zhang J, Wu D, Xu L: HIV-1 Tat protein increases the
permeability of brain endothelial cells by both inhibiting occludin
expression and cleaving occludin via matrix metalloproteinase-9. Brain
Res 2012, 1436:13–19.
34. Moroi S, Saitou M, Fujimoto K, Sakakibara A, Furuse M, Yoshida O, Tsukita S:
Occludin is concentrated at tight junctions of mouse/rat but not human/
guinea pig Sertoli cells in testes. Am J Physiol 1998, 274:C1708–1717.
35. Saitou M, Fujimoto K, Doi Y, Itoh M, Fujimoto T, Furuse M, Takano H, Noda
T, Tsukita S: Occludin-deficient embryonic stem cells can differentiate
into polarized epithelial cells bearing tight junctions. J Cell Biol 1998,
141:397–408.
36. Saitou M, Furuse M, Sasaki H, Schulzke JD, Fromm M, Takano H, Noda T,
Tsukita S: Complex phenotype of mice lacking occludin, a component of
tight junction strands. Mol Biol Cell 2000, 11:4131–4142.
37. Schulzke JD, Gitter AH, Mankertz J, Spiegel S, Seidler U, Amasheh S, Saitou
M, Tsukita S, Fromm M: Epithelial transport and barrier function in
occludin-deficient mice. Biochim Biophys Acta 2005, 1669:34–42.
38. Furuse M, Sasaki H, Tsukita S: Manner of interaction of heterogeneous
claudin species within and between tight junction strands. J Cell Biol
1999, 147:891–903.
39. Mineta K, Yamamoto Y, Yamazaki Y, Tanaka H, Tada Y, Saito K, Tamura A,
Igarashi M, Endo T, Takeuchi K, Tsukita S: Predicted expansion of the
claudin multigene family. FEBS Lett 2011, 585:606–612.
40. Morita K, Furuse M, Fujimoto K, Tsukita S: Claudin multigene family
encoding four-transmembrane domain protein components of tight
junction strands. Proc Natl Acad Sci USA 1999, 96:511–516.
41. Wolburg H, Wolburg-Buchholz K, Kraus J, Rascher-Eggstein G, Liebner S,
Hamm S, Duffner F, Grote EH, Risau W, Engelhardt B: Localization of
claudin-3 in tight junctions of the blood–brain barrier is selectively lost
during experimental autoimmune encephalomyelitis and human
glioblastoma multiforme. Acta Neuropathol 2003, 105:586–592.
42. Morita K, Sasaki H, Furuse M, Tsukita S: Endothelial claudin:
claudin-5/TMVCF constitutes tight junction strands in endothelial
cells. J Cell Biol 1999, 147:185–194.
43. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S:
Size-selective loosening of the blood–brain barrier in claudin-5-deficient
mice. J Cell Biol 2003, 161:653–660.
44. Ohtsuki S, Sato S, Yamaguchi H, Kamoi M, Asashima T, Terasaki T:
Exogenous expression of claudin-5 induces barrier properties in cultured
rat brain capillary endothelial cells. J Cell Physiol 2007, 210:81–86.
45. Piehl C, Piontek J, Cording J, Wolburg H, Blasig IE: Participation of the
second extracellular loop of claudin-5 in paracellular tightening against
ions, small and large molecules. Cell Mol Life Sci 2010, 67:2131–2140.
46. Piontek J, Winkler L, Wolburg H, Muller SL, Zuleger N, Piehl C, Wiesner B,
Krause G, Blasig IE: Formation of tight junction: determinants of
homophilic interaction between classic claudins. FASEB J 2008,
22:146–158.
47. Zhang J, Piontek J, Wolburg H, Piehl C, Liss M, Otten C, Christ A, Willnow TE,
Blasig IE, Abdelilah-Seyfried S: Establishment of a neuroepithelial barrier
by Claudin5a is essential for zebrafish brain ventricular lumen
expansion. Proc Natl Acad Sci USA 2010, 107:1425–1430.
48. Coyne CB, Gambling TM, Boucher RC, Carson JL, Johnson LG: Role of
claudin interactions in airway tight junctional permeability. Am J Physiol
Lung Cell Mol Physiol 2003, 285:L1166–1178.
49. Piontek J, Fritzsche S, Cording J, Richter S, Hartwig J, Walter M, Yu D, Turner
JR, Gehring C, Rahn HP, et al: Elucidating the principles of the molecular
organization of heteropolymeric tight junction strands. Cell Mol Life Sci
2011, 68:3903–3918.
50. Bazzoni G: Pathobiology of junctional adhesion molecules. Antioxid Redox
Signal 2011, 15:1221–1234.
51. Ebnet K, Suzuki A, Ohno S, Vestweber D: Junctional adhesion molecules
(JAMs): more molecules with dual functions? J Cell Sci 2004, 117:19–29.
52. Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA: Identification of
ZO-1: a high molecular weight polypeptide associated with the tight
junction (zonula occludens) in a variety of epithelia. J Cell Biol 1986,
103:755–766.
53. Gumbiner B, Lowenkopf T, Apatira D: Identification of a 160-kDa
polypeptide that binds to the tight junction protein ZO-1. Proc Natl Acad
Sci USA 1991, 88:3460–3464.
54. Haskins J, Gu L, Wittchen ES, Hibbard J, Stevenson BR: ZO-3, a novel
member of the MAGUK protein family found at the tight junction,
interacts with ZO-1 and occludin. J Cell Biol 1998, 141:199–208.
55. Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM: The tight junction
protein ZO-1 establishes a link between the transmembrane protein
occludin and the actin cytoskeleton. J Biol Chem 1998, 273:29745–29753.
56. Itoh M, Morita K, Tsukita S: Characterization of ZO-2 as a MAGUK family
member associated with tight as well as adherens junctions with a
binding affinity to occludin and alpha catenin. J Biol Chem 1999,
274:5981–5986.
57. Itoh M, Furuse M, Morita K, Kubota K, Saitou M, Tsukita S: Direct binding of
three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the
COOH termini of claudins. J Cell Biol 1999, 147:1351–1363.
58. Bazzoni G, Martinez-Estrada OM, Orsenigo F, Cordenonsi M, Citi S, Dejana E:
Interaction of junctional adhesion molecule with the tight junction
components ZO-1, cingulin, and occludin. J Biol Chem 2000,
275:20520–20526.
59. Furuse M, Itoh M, Hirase T, Nagafuchi A, Yonemura S, Tsukita S: Direct
association of occludin with ZO-1 and its possible involvement in the
localization of occludin at tight junctions. J Cell Biol 1994,
127:1617–1626.
60. Umeda K, Ikenouchi J, Katahira-Tayama S, Furuse K, Sasaki H, Nakayama M,
Matsui T, Tsukita S, Furuse M: ZO-1 and ZO-2 independently determine
where claudins are polymerized in tight-junction strand formation. Cell
2006, 126:741–754.
Luissint et al. Fluids and Barriers of the CNS 2012, 9:23 Page 9 of 12
http://www.fluidsbarrierscns.com/content/9/1/23
61. Nusrat A, Brown GT, Tom J, Drake A, Bui TT, Quan C, Mrsny RJ: Multiple
protein interactions involving proposed extracellular loop domains of
the tight junction protein occludin. Mol Biol Cell 2005, 16:1725–1734.
62. Fanning AS, Ma TY, Anderson JM: Isolation and functional characterization
of the actin binding region in the tight junction protein ZO-1.
FASEB J 2002, 16:1835–1837.
63. Izumi Y, Hirose T, Tamai Y, Hirai S, Nagashima Y, Fujimoto T, Tabuse Y,
Kemphues KJ, Ohno S: An atypical PKC directly associates and colocalizes
at the epithelial tight junction with ASIP, a mammalian homologue of
caenorhabditis elegans polarity protein PAR-3. J Cell Biol 1998,
143:95–106.
64. Ebnet K, Aurrand-Lions M, Kuhn A, Kiefer F, Butz S, Zander K, Meyer zu
Brickwedde MK, Suzuki A, Imhof BA, Vestweber D: The junctional adhesion
molecule (JAM) family members JAM-2 and JAM-3 associate with the
cell polarity protein PAR-3: a possible role for JAMs in endothelial cell
polarity. J Cell Sci 2003, 116:3879–3891.
65. Ebnet K, Suzuki A, Horikoshi Y, Hirose T, Meyer Zu Brickwedde MK, Ohno S,
Vestweber D: The cell polarity protein ASIP/PAR-3 directly associates with
junctional adhesion molecule (JAM). EMBO J 2001, 20:3738–3748.
66. Itoh M, Sasaki H, Furuse M, Ozaki H, Kita T, Tsukita S: Junctional adhesion
molecule (JAM) binds to PAR-3: a possible mechanism for the
recruitment of PAR-3 to tight junctions. J Cell Biol 2001, 154:491–497.
67. Suzuki A, Yamanaka T, Hirose T, Manabe N, Mizuno K, Shimizu M, Akimoto K,
Izumi Y, Ohnishi T, Ohno S: Atypical protein kinase C is involved in the
evolutionarily conserved par protein complex and plays a critical role in
establishing epithelia-specific junctional structures. J Cell Biol 2001,
152:1183–1196.
68. Joberty G, Petersen C, Gao L, Macara IG: The cell-polarity protein Par6 links
Par3 and atypical protein kinase C to Cdc42. Nat Cell Biol 2000,
2:531–539.
69. Lin D, Edwards AS, Fawcett JP, Mbamalu G, Scott JD, Pawson T: A
mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC
signalling and cell polarity. Nat Cell Biol 2000, 2:540–547.
70. Daneman R, Zhou L, Agalliu D, Cahoy JD, Kaushal A, Barres BA: The mouse
blood–brain barrier transcriptome: a new resource for understanding
the development and function of brain endothelial cells. PLoS One 2010,
5:e13741.
71. Denker BM, Saha C, Khawaja S, Nigam SK: Involvement of a heterotrimeric
G protein alpha subunit in tight junction biogenesis. J Biol Chem 1996,
271:25750–25753.
72. Saha C, Nigam SK, Denker BM: Involvement of Galphai2 in the
maintenance and biogenesis of epithelial cell tight junctions. J Biol Chem
1998, 273:21629–21633.
73. Fabian G, Szabo CA, Bozo B, Greenwood J, Adamson P, Deli MA, Joo F,
Krizbai IA, Szucs M: Expression of G-protein subtypes in cultured cerebral
endothelial cells. Neurochem Int 1998, 33:179–185.
74. Adamson P, Wilbourn B, Etienne-Manneville S, Calder V, Beraud E, Milligan
G, Couraud PO, Greenwood J: Lymphocyte trafficking through the
blood–brain barrier is dependent on endothelial cell heterotrimeric
G-protein signaling. FASEB J 2002, 16:1185–1194.
75. Pero RS, Borchers MT, Spicher K, Ochkur SI, Sikora L, Rao SP, Abdala-Valencia
H, O’Neill KR, Shen H, McGarry MP, et al: Galphai2-mediated signaling
events in the endothelium are involved in controlling leukocyte
extravasation. Proc Natl Acad Sci USA 2007, 104:4371–4376.
76. Abbott NJ, Ronnback L, Hansson E: Astrocyte-endothelial interactions at
the blood–brain barrier. Nat Rev Neurosci 2006, 7:41–53.
77. Janzer RC, Raff MC: Astrocytes induce blood–brain barrier properties in
endothelial cells. Nature 1987, 325:253–257.
78. Bonkowski D, Katyshev V, Balabanov RD, Borisov A, Dore-Duffy P: The CNS
microvascular pericyte: pericyte-astrocyte crosstalk in the regulation of
tissue survival. Fluids Barriers CNS 2011, 8:8.
79. Sa-Pereira I, Brites D, Brito MA: Neurovascular unit: a focus on pericytes.
Mol Neurobiol 2012, 45:327–347.
80. Winkler EA, Bell RD, Zlokovic BV: Pericyte-specific expression of PDGF beta
receptor in mouse models with normal and deficient PDGF beta
receptor signaling. Mol Neurodegener 2010, 5:32.
81. Arthur FE, Shivers RR, Bowman PD: Astrocyte-mediated induction of tight
junctions in brain capillary endothelium: an efficient in vitro model. Brain
Res 1987, 433:155–159.
82. Colgan OC, Collins NT, Ferguson G, Murphy RP, Birney YA, Cahill PA,
Cummins PM: Influence of basolateral condition on the regulation of
brain microvascular endothelial tight junction properties and barrier
function. Brain Res 2008, 1193:84–92.
83. Lee SW, Kim WJ, Choi YK, Song HS, Son MJ, Gelman IH, Kim YJ, Kim KW:
SSeCKS regulates angiogenesis and tight junction formation in
blood–brain barrier. Nat Med 2003, 9:900–906.
84. Neuhaus J, Risau W, Wolburg H: Induction of blood–brain barrier
characteristics in bovine brain endothelial cells by rat astroglial cells in
transfilter coculture. Ann N Y Acad Sci 1991, 633:578–580.
85. Rubin LL, Hall DE, Porter S, Barbu K, Cannon C, Horner HC, Janatpour M,
Liaw CW, Manning K, Morales J, et al: A cell culture model of the
blood–brain barrier. J Cell Biol 1991, 115:1725–1735.
86. Tao-Cheng JH, Nagy Z, Brightman MW: Tight junctions of brain
endothelium in vitro are enhanced by astroglia. J Neurosci 1987,
7:3293–3299.
87. Wolburg H, Neuhaus J, Kniesel U, Krauss B, Schmid EM, Ocalan M, Farrell C,
Risau W: Modulation of tight junction structure in blood–brain barrier
endothelial cells. Effects of tissue culture, second messengers and
cocultured astrocytes. J Cell Sci 1994, 107(Pt 5):1347–1357.
88. Hori S, Ohtsuki S, Hosoya K, Nakashima E, Terasaki T: A pericyte-derived
angiopoietin-1 multimeric complex induces occludin gene expression in
brain capillary endothelial cells through Tie-2 activation in vitro.
J Neurochem 2004, 89:503–513.
89. Daneman R, Zhou L, Kebede AA, Barres BA: Pericytes are required for
blood–brain barrier integrity during embryogenesis. Nature 2010,
468:562–566.
90. Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, He L,
Norlin J, Lindblom P, Strittmatter K, et al: Pericytes regulate the
blood–brain barrier. Nature 2010, 468:557–561.
91. Dohgu S, Takata F, Yamauchi A, Nakagawa S, Egawa T, Naito M, Tsuruo T,
Sawada Y, Niwa M, Kataoka Y: Brain pericytes contribute to the induction
and up-regulation of blood–brain barrier functions through transforming
growth factor-beta production. Brain Res 2005, 1038:208–215.
92. Liebner S, Czupalla CJ, Wolburg H: Current concepts of blood–brain
barrier development. Int J Dev Biol 2011, 55:467–476.
93. Osada T, Gu YH, Kanazawa M, Tsubota Y, Hawkins BT, Spatz M, Milner R, del
Zoppo GJ: Interendothelial claudin-5 expression depends on cerebral
endothelial cell-matrix adhesion by beta(1)-integrins. J Cereb Blood Flow
Metab 2011, 31:1972–1985.
94. Zovein AC, Luque A, Turlo KA, Hofmann JJ, Yee KM, Becker MS, Fassler R,
Mellman I, Lane TF, Iruela-Arispe ML: Beta1 integrin establishes endothelial
cell polarity and arteriolar lumen formation via a Par3-dependent
mechanism. Dev Cell 2010, 18:39–51.
95. Alvarez JI, Dodelet-Devillers A, Kebir H, Ifergan I, Fabre PJ, Terouz S, Sabbagh
M, Wosik K, Bourbonniere L, Bernard M, et al: The Hedgehog pathway
promotes blood–brain barrier integrity and CNS immune quiescence.
Science 2011, 334:1727–1731.
96. Liebner S, Corada M, Bangsow T, Babbage J, Taddei A, Czupalla CJ, Reis M,
Felici A, Wolburg H, Fruttiger M, et al: Wnt/beta-catenin signaling controls
development of the blood–brain barrier. J Cell Biol 2008, 183:409–417.
97. Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, Pirazzoli V, Potente
M, Daly C, Dimmeler S, Dejana E: Endothelial adherens junctions control
tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat
Cell Biol 2008, 10:923–934.
98. Lampugnani MG, Orsenigo F, Rudini N, Maddaluno L, Boulday G, Chapon F,
Dejana E: CCM1 regulates vascular-lumen organization by inducing
endothelial polarity. J Cell Sci 2010, 123:1073–1080.
99. Chien AJ, Conrad WH, Moon RT: A Wnt survival guide: from flies to
human disease. J Invest Dermatol 2009, 129:1614–1627.
100. Stenman JM, Rajagopal J, Carroll TJ, Ishibashi M, McMahon J, McMahon AP:
Canonical Wnt signaling regulates organ-specific assembly and
differentiation of CNS vasculature. Science 2008, 322:1247–1250.
101. Ye X, Wang Y, Cahill H, Yu M, Badea TC, Smallwood PM, Peachey NS,
Nathans J: Norrin, frizzled-4, and Lrp5 signaling in endothelial cells
controls a genetic program for retinal vascularization. Cell 2009,
139:285–298.
102. Daneman R, Agalliu D, Zhou L, Kuhnert F, Kuo CJ, Barres BA:
Wnt/beta-catenin signaling is required for CNS, but not non-CNS,
angiogenesis. Proc Natl Acad Sci USA 2009, 106:641–646.
103. Paolinelli R, Corada M, Orsenigo F, Dejana E: The molecular basis of the
blood brain barrier differentiation and maintenance. Is it still a mystery?
Pharmacol Res 2011, 63:165–171.
Luissint et al. Fluids and Barriers of the CNS 2012, 9:23 Page 10 of 12
http://www.fluidsbarrierscns.com/content/9/1/23
104. Wu C, Ivars F, Anderson P, Hallmann R, Vestweber D, Nilsson P, Robenek H,
Tryggvason K, Song J, Korpos E, et al: Endothelial basement membrane
laminin alpha5 selectively inhibits T lymphocyte extravasation into the
brain. Nat Med 2009, 15:519–527.
105. Barber AJ, Lieth E: Agrin accumulates in the brain microvascular basal
lamina during development of the blood–brain barrier. Dev Dyn 1997,
208:62–74.
106. Rascher G, Fischmann A, Kroger S, Duffner F, Grote EH, Wolburg H:
Extracellular matrix and the blood–brain barrier in glioblastoma
multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol
2002, 104:85–91.
107. Gavard J: Breaking the VE-cadherin bonds. FEBS Lett 2009, 583:1–6.
108. Dejana E, Giampietro C: Vascular endothelial-cadherin and vascular
stability. Curr Opin Hematol 2012, 19:218–223.
109. Harris ES, Nelson WJ: VE-cadherin: at the front, center, and sides of
endothelial cell organization and function. Curr Opin Cell Biol 2010,
22:651–658.
110. Stanness KA, Westrum LE, Fornaciari E, Mascagni P, Nelson JA, Stenglein SG,
Myers T, Janigro D: Morphological and functional characterization of an
in vitro blood–brain barrier model. Brain Res 1997, 771:329–342.
111. Mairey E, Genovesio A, Donnadieu E, Bernard C, Jaubert F, Pinard E, Seylaz J,
Olivo-Marin JC, Nassif X, Dumenil G: Cerebral microcirculation shear stress
levels determine Neisseria meningitidis attachment sites along the
blood–brain barrier. J Exp Med 2006, 203:1939–1950.
112. Santaguida S, Janigro D, Hossain M, Oby E, Rapp E, Cucullo L: Side by side
comparison between dynamic versus static models of blood–brain
barrier in vitro: a permeability study. Brain Res 2006, 1109:1–13.
113. Colgan OC, Ferguson G, Collins NT, Murphy RP, Meade G, Cahill PA,
Cummins PM: Regulation of bovine brain microvascular endothelial tight
junction assembly and barrier function by laminar shear stress. Am J
Physiol Heart Circ Physiol 2007, 292:H3190–3197.
114. Krizanac-Bengez L, Mayberg MR, Cunningham E, Hossain M, Ponnampalam
S, Parkinson FE, Janigro D: Loss of shear stress induces
leukocyte-mediated cytokine release and blood–brain barrier failure in
dynamic in vitro blood–brain barrier model. J Cell Physiol 2006, 206:68–77.
115. Siddharthan V, Kim YV, Liu S, Kim KS: Human astrocytes/astrocyte-
conditioned medium and shear stress enhance the barrier properties of
human brain microvascular endothelial cells. Brain Res 2007, 1147:39–50.
116. Cucullo L, Hossain M, Puvenna V, Marchi N, Janigro D: The role of shear
stress in blood–brain barrier endothelial physiology. BMC Neurosci 2011,
12:40.
117. Walsh TG, Murphy RP, Fitzpatrick P, Rochfort KD, Guinan AF, Murphy A,
Cummins PM: Stabilization of brain microvascular endothelial barrier
function by shear stress involves VE-cadherin signaling leading to
modulation of pTyr-occludin levels. J Cell Physiol 2011, 226:3053–3063.
118. Cummins PM: Occludin: one protein, many forms. Mol Cell Biol 2012,
32:242–250.
119. Dorfel MJ, Huber O: Modulation of tight junction structure and function
by kinases and phosphatases targeting occludin. J Biomed Biotechnol
2012, 2012:807356.
120. Soma T, Chiba H, Kato-Mori Y, Wada T, Yamashita T, Kojima T, Sawada N:
Thr(207) of claudin-5 is involved in size-selective loosening
of the endothelial barrier by cyclic AMP. Exp Cell Res 2004,
300:202–212.
121. Willis CL, Meske DS, Davis TP: Protein kinase C activation modulates
reversible increase in cortical blood–brain barrier permeability and tight
junction protein expression during hypoxia and posthypoxic
reoxygenation. J Cereb Blood Flow Metab 2010, 30:1847–1859.
122. Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y:
HIV-1 gp120 compromises blood–brain barrier integrity and enhances
monocyte migration across blood–brain barrier: implication for viral
neuropathogenesis. J Cereb Blood Flow Metab 2007, 27:123–134.
123. Yamamoto M, Ramirez SH, Sato S, Kiyota T, Cerny RL, Kaibuchi K, Persidsky
Y, Ikezu T: Phosphorylation of claudin-5 and occludin by rho kinase in
brain endothelial cells. Am J Pathol 2008, 172:521–533.
124. Stamatovic SM, Dimitrijevic OB, Keep RF, Andjelkovic AV: Protein kinase
Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial
permeability. J Biol Chem 2006, 281:8379–8388.
125. Haorah J, Knipe B, Leibhart J, Ghorpade A, Persidsky Y: Alcohol-induced
oxidative stress in brain endothelial cells causes blood–brain barrier
dysfunction. J Leukoc Biol 2005, 78:1223–1232.
126. Haorah J, Heilman D, Knipe B, Chrastil J, Leibhart J, Ghorpade A, Miller DW,
Persidsky Y: Ethanol-induced activation of myosin light chain kinase leads
to dysfunction of tight junctions and blood–brain barrier compromise.
Alcohol Clin Exp Res 2005, 29:999–1009.
127. Kuhlmann CR, Tamaki R, Gamerdinger M, Lessmann V, Behl C, Kempski OS,
Luhmann HJ: Inhibition of the myosin light chain kinase prevents
hypoxia-induced blood–brain barrier disruption. J Neurochem 2007,
102:501–507.
128. Takenaga Y, Takagi N, Murotomi K, Tanonaka K, Takeo S: Inhibition of Src
activity decreases tyrosine phosphorylation of occludin in brain
capillaries and attenuates increase in permeability of the blood–brain
barrier after transient focal cerebral ischemia. J Cereb Blood Flow Metab
2009, 29:1099–1108.
129. Andras IE, Deli MA, Veszelka S, Hayashi K, Hennig B, Toborek M: The NMDA
and AMPA/KA receptors are involved in glutamate-induced alterations
of occludin expression and phosphorylation in brain endothelial cells.
J Cereb Blood Flow Metab 2007, 27:1431–1443.
130. Shen W, Li S, Chung SH, Zhu L, Stayt J, Su T, Couraud PO, Romero IA,
Weksler B, Gillies MC: Tyrosine phosphorylation of VE-cadherin and
claudin-5 is associated with TGF-beta1-induced permeability of centrally
derived vascular endothelium. Eur J Cell Biol 2011, 90:323–332.
131. Staddon JM, Herrenknecht K, Smales C, Rubin LL: Evidence that tyrosine
phosphorylation may increase tight junction permeability. J Cell Sci 1995,
108(Pt 2):609–619.
132. Stamatovic SM, Keep RF, Wang MM, Jankovic I, Andjelkovic AV: Caveolae-
mediated internalization of occludin and claudin-5 during CCL2-induced
tight junction remodeling in brain endothelial cells. J Biol Chem 2009,
284:19053–19066.
133. Tai LM, Holloway KA, Male DK, Loughlin AJ, Romero IA: Amyloid-beta-
induced occludin down-regulation and increased permeability in human
brain endothelial cells is mediated by MAPK activation. J Cell Mol Med
2010, 14:1101–1112.
134. Andras IE, Pu H, Tian J, Deli MA, Nath A, Hennig B, Toborek M: Signaling
mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in
brain endothelial cells. J Cereb Blood Flow Metab 2005, 25:1159–1170.
135. Fischer S, Wiesnet M, Marti HH, Renz D, Schaper W: Simultaneous
activation of several second messengers in hypoxia-induced
hyperpermeability of brain derived endothelial cells. J Cell Physiol 2004,
198:359–369.
136. Mark KS, Davis TP: Cerebral microvascular changes in permeability and
tight junctions induced by hypoxia-reoxygenation. Am J Physiol Heart Circ
Physiol 2002, 282:H1485–1494.
137. Koto T, Takubo K, Ishida S, Shinoda H, Inoue M, Tsubota K, Okada Y, Ikeda E:
Hypoxia disrupts the barrier function of neural blood vessels through
changes in the expression of claudin-5 in endothelial cells. Am J Pathol
2007, 170:1389–1397.
138. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR: VEGF-mediated
disruption of endothelial CLN-5 promotes blood–brain barrier
breakdown. Proc Natl Acad Sci USA 2009, 106:1977–1982.
139. Jiao H, Wang Z, Liu Y, Wang P, Xue Y: Specific role of tight junction
proteins claudin-5, occludin, and ZO-1 of the blood–brain barrier in a
focal cerebral ischemic insult. J Mol Neurosci 2011, 44:130–139.
140. Afonso PV, Ozden S, Prevost MC, Schmitt C, Seilhean D, Weksler B, Couraud
PO, Gessain A, Romero IA, Ceccaldi PE: Human blood–brain barrier
disruption by retroviral-infected lymphocytes: role of myosin light chain
kinase in endothelial tight-junction disorganization. J Immunol 2007,
179:2576–2583.
141. Schreibelt G, Kooij G, Reijerkerk A, van Doorn R, Gringhuis SI, van der Pol S,
Weksler BB, Romero IA, Couraud PO, Piontek J, et al: Reactive oxygen
species alter brain endothelial tight junction dynamics via RhoA, PI3
kinase, and PKB signaling. FASEB J 2007, 21:3666–3676.
142. Clarke H, Soler AP, Mullin JM: Protein kinase C activation leads to
dephosphorylation of occludin and tight junction permeability increase
in LLC-PK1 epithelial cell sheets. J Cell Sci 2000, 113(Pt 18):3187–3196.
143. Sakakibara A, Furuse M, Saitou M, Ando-Akatsuka Y, Tsukita S: Possible
involvement of phosphorylation of occludin in tight junction formation.
J Cell Biol 1997, 137:1393–1401.
144. Morgan L, Shah B, Rivers LE, Barden L, Groom AJ, Chung R, Higazi D,
Desmond H, Smith T, Staddon JM: Inflammation and dephosphorylation
of the tight junction protein occludin in an experimental model of
multiple sclerosis. Neuroscience 2007, 147:664–673.
Luissint et al. Fluids and Barriers of the CNS 2012, 9:23 Page 11 of 12
http://www.fluidsbarrierscns.com/content/9/1/23
145. Ishizaki T, Chiba H, Kojima T, Fujibe M, Soma T, Miyajima H, Nagasawa K,
Wada I, Sawada N: Cyclic AMP induces phosphorylation of claudin-5
immunoprecipitates and expression of claudin-5 gene in
blood–brain-barrier endothelial cells via protein kinase A-dependent
and -independent pathways. Exp Cell Res 2003, 290:275–288.
146. Bruckener KE, El Baya A, Galla HJ, Schmidt MA: Permeabilization in a
cerebral endothelial barrier model by pertussis toxin involves the PKC
effector pathway and is abolished by elevated levels of cAMP.
J Cell Sci 2003, 116:1837–1846.
147. Desai TR, Leeper NJ, Hynes KL, Gewertz BL: Interleukin-6 causes
endothelial barrier dysfunction via the protein kinase C pathway.
J Surg Res 2002, 104:118–123.
148. Andreeva AY, Krause E, Muller EC, Blasig IE, Utepbergenov DI: Protein
kinase C regulates the phosphorylation and cellular localization of
occludin. J Biol Chem 2001, 276:38480–38486.
149. Stuart RO, Nigam SK: Regulated assembly of tight junctions by protein
kinase C. Proc Natl Acad Sci USA 1995, 92:6072–6076.
150. Hofmann J: The potential for isoenzyme-selective modulation of protein
kinase C. FASEB J 1997, 11:649–669.
151. Fleegal MA, Hom S, Borg LK, Davis TP: Activation of PKC modulates
blood–brain barrier endothelial cell permeability changes induced by
hypoxia and posthypoxic reoxygenation. Am J Physiol Heart Circ Physiol
2005, 289:H2012–2019.
152. Andreeva AY, Piontek J, Blasig IE, Utepbergenov DI: Assembly of tight
junction is regulated by the antagonism of conventional and novel
protein kinase C isoforms. Int J Biochem Cell Biol 2006, 38:222–233.
153. Harrington EO, Brunelle JL, Shannon CJ, Kim ES, Mennella K, Rounds S: Role
of protein kinase C isoforms in rat epididymal microvascular endothelial
barrier function. Am J Respir Cell Mol Biol 2003, 28:626–636.
154. Sonobe Y, Takeuchi H, Kataoka K, Li H, Jin S, Mimuro M, Hashizume Y, Sano
Y, Kanda T, Mizuno T, Suzumura A: Interleukin-25 expressed by brain
capillary endothelial cells maintains blood–brain barrier function in a
protein kinase Cepsilon-dependent manner. J Biol Chem 2009,
284:31834–31842.
155. Goldstein B, Macara IG: The PAR proteins: fundamental players in animal
cell polarization. Dev Cell 2007, 13:609–622.
156. Coureuil M, Mikaty G, Miller F, Lecuyer H, Bernard C, Bourdoulous S,
Dumenil G, Mege RM, Weksler BB, Romero IA, et al: Meningococcal type IV
pili recruit the polarity complex to cross the brain endothelium. Science
2009, 325:83–87.
157. Iden S, Rehder D, August B, Suzuki A, Wolburg-Buchholz K, Wolburg H,
Ohno S, Behrens J, Vestweber D, Ebnet K: A distinct PAR complex
associates physically with VE-cadherin in vertebrate endothelial cells.
EMBO Rep 2006, 7:1239–1246.
158. Birukova AA, Smurova K, Birukov KG, Kaibuchi K, Garcia JG, Verin AD: Role of
Rho GTPases in thrombin-induced lung vascular endothelial cells barrier
dysfunction. Microvasc Res 2004, 67:64–77.
159. Boivin D, Bilodeau D, Beliveau R: Regulation of cytoskeletal functions by
Rho small GTP-binding proteins in normal and cancer cells. Can J Physiol
Pharmacol 1996, 74:801–810.
160. Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV: Potential role of MCP-1
in endothelial cell tight junction ‘opening’: signaling via Rho and Rho
kinase. J Cell Sci 2003, 116:4615–4628.
161. Persidsky Y, Heilman D, Haorah J, Zelivyanskaya M, Persidsky R, Weber GA,
Shimokawa H, Kaibuchi K, Ikezu T: Rho-mediated regulation of tight
junctions during monocyte migration across the blood–brain barrier in
HIV-1 encephalitis (HIVE). Blood 2006, 107:4770–4780.
162. Adamson P, Etienne S, Couraud PO, Calder V, Greenwood J: Lymphocyte
migration through brain endothelial cell monolayers involves signaling
through endothelial ICAM-1 via a rho-dependent pathway. J Immunol
1999, 162:2964–2973.
163. Etienne S, Adamson P, Greenwood J, Strosberg AD, Cazaubon S, Couraud
PO: ICAM-1 signaling pathways associated with Rho activation in
microvascular brain endothelial cells. J Immunol 1998, 161:5755–5761.
164. Engelhardt B, Wolburg H: Mini-review: Transendothelial migration of
leukocytes: through the front door or around the side of the house?
Eur J Immunol 2004, 34:2955–2963.
165. Goeckeler ZM, Wysolmerski RB: Myosin light chain kinase-regulated
endothelial cell contraction: the relationship between isometric tension,
actin polymerization, and myosin phosphorylation. J Cell Biol 1995,
130:613–627.
166. Hixenbaugh EA, Goeckeler ZM, Papaiya NN, Wysolmerski RB, Silverstein SC,
Huang AJ: Stimulated neutrophils induce myosin light chain
phosphorylation and isometric tension in endothelial cells. Am J Physiol
1997, 273:H981–988.
167. Moy AB, Shasby SS, Scott BD, Shasby DM: The effect of histamine and
cyclic adenosine monophosphate on myosin light chain
phosphorylation in human umbilical vein endothelial cells.
J Clin Invest 1993, 92:1198–1206.
168. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW: Vascular
endothelial growth factor induces rapid phosphorylation of tight
junction proteins occludin and zonula occluden 1. A potential
mechanism for vascular permeability in diabetic retinopathy and tumors.
J Biol Chem 1999, 274:23463–23467.
169. Nico B, Mangieri D, Crivellato E, Longo V, De Giorgis M, Capobianco C, Corsi
P, Benagiano V, Roncali L, Ribatti D: HIF activation and VEGF
overexpression are coupled with ZO-1 up-phosphorylation in the brain
of dystrophic mdx mouse. Brain Pathol 2007, 17:399–406.
170. Kago T, Takagi N, Date I, Takenaga Y, Takagi K, Takeo S: Cerebral ischemia
enhances tyrosine phosphorylation of occludin in brain capillaries.
Biochem Biophys Res Commun 2006, 339:1197–1203.
171. Wang W, Dentler WL, Borchardt RT: VEGF increases BMEC monolayer
permeability by affecting occludin expression and tight junction
assembly. Am J Physiol Heart Circ Physiol 2001, 280:H434–440.
172. Frank PG, Woodman SE, Park DS, Lisanti MP: Caveolin, caveolae, and
endothelial cell function. Arterioscler Thromb Vasc Biol 2003, 23:1161–1168.
173. Sprenger RR, Fontijn RD, van Marle J, Pannekoek H, Horrevoets AJ: Spatial
segregation of transport and signalling functions between human
endothelial caveolae and lipid raft proteomes. Biochem J 2006,
400:401–410.
174. Nusrat A, Parkos CA, Verkade P, Foley CS, Liang TW, Innis-Whitehouse W,
Eastburn KK, Madara JL: Tight junctions are membrane microdomains.
J Cell Sci 2000, 113(Pt 10):1771–1781.
175. Shen L, Turner JR: Actin depolymerization disrupts tight junctions via
caveolae-mediated endocytosis. Mol Biol Cell 2005, 16:3919–3936.
176. Andras IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M: HIV-1 Tat protein
alters tight junction protein expression and distribution in cultured brain
endothelial cells. J Neurosci Res 2003, 74:255–265.
177. Urban NT, Willig KI, Hell SW, Nagerl UV: STED nanoscopy of actin dynamics
in synapses deep inside living brain slices. Biophys J 2011, 101:1277–1284.
178. Keene SD, Greco TM, Parastatidis I, Lee SH, Hughes EG, Balice-Gordon RJ,
Speicher DW, Ischiropoulos H: Mass spectrometric and computational
analysis of cytokine-induced alterations in the astrocyte secretome.
Proteomics 2009, 9:768–782.
179. Picotti P, Aebersold R: Selected reaction monitoring-based proteomics:
workflows, potential, pitfalls and future directions. Nat Methods 2012,
9:555–566.
180. Uchida Y, Ohtsuki S, Katsukura Y, Ikeda C, Suzuki T, Kamiie J, Terasaki T:
Quantitative targeted absolute proteomics of human blood–brain barrier
transporters and receptors. J Neurochem 2011, 117:333–345.
doi:10.1186/2045-8118-9-23
Cite this article as: Luissint et al.: Tight junctions at the blood brain
barrier: physiological architecture and disease-associated dysregulation.
Fluids and Barriers of the CNS 2012 9:23.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Luissint et al. Fluids and Barriers of the CNS 2012, 9:23 Page 12 of 12
http://www.fluidsbarrierscns.com/content/9/1/23
